Oric Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $109.8M | $114.1M | $85.2M | $61.7M | $56.9M |
| Operating expenses | $143.0M | $142.9M | $110.8M | $91.8M | $78.9M |
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M |
| Balance Sheet | |||||
| Cash and equivalents | $45.7M | $59.4M | $23.4M | $66.8M | $226.0M |
| Current assets | $288.5M | $262.2M | $212.6M | $210.5M | $240.5M |
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M |
| Current liabilities | $20.4M | $24.8M | $20.5M | $15.4M | $15.2M |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M |
| Stockholders' equity | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$111.0M | -$112.7M | -$85.7M | -$75.1M | -$59.5M |
| Depreciation and amortization | $1.2M | $1.1M | $1.0M | $966,000 | $897,000 |
| Stock-based compensation | $25.0M | $20.2M | $15.2M | $14.5M | $12.9M |
| Capital expenditure | $712,000 | $1.2M | $849,000 | $2.1M | $939,000 |
| Free cash flow | -$111.7M | -$113.8M | -$86.5M | -$77.2M | -$60.5M |
Shares outstanding 103.5M · Free float 84.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.